Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 304

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity

Open access
Guo, Chuansheng, You, Zhiyuan, Shi, Hao, Sun, Yu, Du, Xingrong, Palacios, Gustavo, Guy, Cliff, Yuan, Sujing, Chapman, Nicole M., Lim, Seon Ah, Sun, Xiang, Saravia, Jordy, Rankin, Sherri, Dhungana, Yogesh, Chi, Hongbo·2023·Nature

Abstract

Cancer cells evade T cell-mediated killing through tumour–immune interactions whose mechanisms are not well understood 1,2 . Dendritic cells (DCs), especially type-1 conventional DCs (cDC1s), mediate T cell priming and therapeutic efficacy against tumours 3 . DC functions are orchestrated by pattern recognition receptors 3–5 , although other signals involved remain incompletely defined. Nutrients are emerging mediators of adaptive immunity 6–8 , but whether nutrients affect DC function or communication between innate and adaptive immune cells is largely unresolved. Here we establish glutamine as an intercellular metabolic checkpoint that dictates tumour–cDC1 crosstalk and licenses cDC1 function in activating cytotoxic T cells. Intratumoral glutamine supplementation inhibits tumour growth by augmenting cDC1-mediated CD8 + T cell immunity, and overcomes therapeutic resistance to checkpoint blockade and T cell-mediated immunotherapies. Mechanistically, tumour cells and cDC1s compete for glutamine uptake via the transporter SLC38A2 to tune anti-tumour immunity. Nutrient screening and integrative analyses show that glutamine is the dominant amino acid in promoting cDC1 function. Further, glutamine signalling via FLCN impinges on TFEB function. Loss of FLCN in DCs selectively impairs cDC1 function in vivo in a TFEB-dependent manner and phenocopies SLC38A2 deficiency by eliminating the anti-tumour therapeutic effect of glutamine supplementation. Our findings establish glutamine-mediated intercellular metabolic crosstalk between tumour cells and cDC1s that underpins tumour immune evasion, and reveal glutamine acquisition and signalling in cDC1s as limiting events for DC activation and putative targets for cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06299-8

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 304

Metadata

Authors
Guo, C., You, Z., Shi, H., Sun, Y., Du, X., Palacios, G., Guy, C., Yuan, S., Chapman, N. M., Lim, S. A., Sun, X., Saravia, J., Rankin, S., Dhungana, Y., & Chi, H.
Venue
Nature
Published
2023-07-05
Volume
620
Issue
7972
Pages
200-208
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4383265657
Cited by
304
References
69
FWCI
26.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. https://app.cochat.ai/papers/10.1038/s41586-023-06299-8
The paper
Guo, C., You, Z., Shi, H., Sun, Y., Du, X., Palacios, G., Guy, C., Yuan, S., Chapman, N. M., Lim, S. A., Sun, X., Saravia, J., Rankin, S., Dhungana, Y., & Chi, H. (2023). SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. https://doi.org/10.1038/s41586-023-06299-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.